Steven H. Holtzman
Independent DirectorMr. Steven H. Holtzman, also known as Steve, B.Phil, D.Phil., is Co- Founder & Director of Shoreline Biosciences, Inc. He serves as Bio Advisor at Amplify Partners, LLC from July 2026. Mr. Holtzman is Member of Advisory Board at Arctoris Limited and also serves as the Executive Chairman at Manifold Biotechnologies, Inc. Mr. Holtzman serves as an Independent Director and served as Chairman of the Board at CAMP4 Therapeutics Corporation since October 2019 until September 09, 2025. He serves as the Chairman at Hangzhou Qihan Biotechnology Co., Ltd. He served as the Chief Executive Officer and President at Decibel Therapeutics, Inc. since July 13, 2016 until January 17, 2020. Mr. Holtzman has been Strategic Business Advisor at Compugen Ltd. since May 10, 2016. He had been Advisor for PureTech Health plc since October 13, 2016. Mr. Holtzman served as an Executive Vice President of Corporate Development at Biogen Inc. from January 5, 2011 to March 31, 2016. He served as Executive Vice President of Corporate Development at Biogen Idec Ltd. since January 2011. He has many years of strategic, operational and management experience in the biopharmaceutical industry and in particular, experience in growing and leading companies and business units to generate significant value, as well as deep understanding of global pharmaceutical markets. He founded Infinity Pharmaceuticals, Inc. in 2006 and served as its Executive Chairman and served as its Chief Executive Officer from September 2006 to January 1, 2010 and President from October 2007 to October 2008. He served as the President of Infinity Discovery from July 2001 to February 2006. He served as the Chief Business Officer of Millennium Pharmaceuticals, Inc. (now Takeda Oncology) from 1994 to 2001. In this role, at various times, he held management responsibility for all of Millennium’s activities in the areas of business development, M&A, licensing, intellectual property and corporate law, human resources, finance, public policy and corporate communications. Mr. Holtzman founded DNX Corp in 1986 and served as its Executive Vice President and President of DNX Bio-Therapeutics Inc. from 1986 to 1994. He co-founded Infinity Discovery, Inc. and served as its Chief Executive Officer and Chairman from 2001 to 2006. He also served as Non-Executive Chairman of Infinity Pharmaceuticals, Inc. from September 2006 to December 31, 2010. He served as Co-Chairman at Satori Pharmaceuticals Incorporated since April 2010. He served as the Chairman of the Board at Anadys Pharmaceuticals Inc. from July 2010 to January 4, 2011. He has been Director of Warp Drive Bio, LLC since October 17, 2016. He had been a Director of Decibel Therapeutics, Inc. since July 13, 2016 until January 2020. He serves as a Director at Biotechnology Industry Organization and Sartori Pharmaceuticals, Inc. (US). He had been a Non-Executive Director of Molecular Partners AG since May 2014 until 2026. He serves as Member of Business Advisory Board and Non-Voting Director at Evrys Bio, LLC (formerly known as FORGE Life Science, LLC). He served as Director at Pharmaceuticals Incorporated since 2009. He served as a Director of Archemix Corp. He served as Director at PMV Pharmaceutcals, Inc. since April 30, 2014. He served as a Director of DNX Corp. He served as an Independent Director of Anadys Pharmaceuticals Inc. from August 2004 to January 4, 2011. He served as a Member of Supervisory Board at uniQure N.V. from September 20, 2010 to January 3, 2011. He served as a Member of Supervisory Board at Amsterdam Molecular Therapeutics (AMT) Holding N.V from September 20, 2010 to January 3, 2011. From 1996 to 2001, he was a Presidential Appointee to the United States National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He was an Instructor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. in the 1970s. He also served as a Member and Vice Chair of The Board at the Hastings Center for the Life Sciences. He is a Trustee of The Hastings Center for Bioethics and the Berklee College of Music. He was a Founding Executive Director of the Ohio Edison Program since 1980. Mr. Holtzman received a BA in Philosophy from Michigan State University in 1976 and a B.Phil. in Philosophy from Corpus Christi College, Oxford University in 1979, which he attended as a Rhodes Scholar. He holds D.Phil. from Oxford University. He had been a Director of Ataxion, Inc. since March 2014; Visterra, Inc., since April 21, 2016 and The Sync Project since May 2016. He is the chair of the boards of directors of Qihan Biotech and a founder and member of the board of directors of Shoreline Bio, each private biotechnology companies. Since January 2020, he has served as a strategic advisor to Decibel Therapeutics. He is a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School.
Positions
- Company NameCamp4 Therapeutics CorporationStock CodeCAMPPositionIndependent Director
